Roche's Enicepatide Cuts HbA1c 2.65% at 48 Weeks in Phase II Diabetes Trial

Roche (RO.SW, ROG.SW) reported positive topline results from the Phase II CT-388-104 trial of enicepatide in adults with type 2 diabetes and overweight or obesity, with a mean HbA1c reduction of 2.65% at 48 weeks. The drug met both primary endpoints, showing dose-dependent efficacy, according to the Sept. 22, 2026, announcement. Enicepatide is being developed across the company's metabolic disease portfolio. Roche said the findings support advancing late-stage development. Full data have not yet been published, and the company did not disclose detailed safety results in the topline release.